Prospective, Multicentric, Large Scale Observational Study to Evaluate Effectiveness and Safety of Nexavar in Advanced Renal Cell Carcinoma.

Trial Profile

Prospective, Multicentric, Large Scale Observational Study to Evaluate Effectiveness and Safety of Nexavar in Advanced Renal Cell Carcinoma.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2015

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms POWER-NEXT
  • Sponsors Bayer
  • Most Recent Events

    • 29 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 28 Jul 2014 Planned initiation date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 10 Mar 2014 Planned initiation date changed from 1 Sep 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top